From infection to immunotherapy: Host immune responses to bacteria at the bladder mucosa

Mucosal Immunology

Volumn 6, Issue 6, 2013, Pages 1041-1053

  Ingersoll, M A ^a,b   Albert, M L ^a,b  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; FORSKOLIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ASYMPTOMATIC BACTERIURIA; BACTERIAL COLONIZATION; BCG IMMUNOTHERAPY; BLADDER CANCER; BLADDER MUCOSA; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMMENSAL; DEFENSE MECHANISM; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; TH1 CELL; TH2 CELL; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ADAPTIVE IMMUNITY; ANEMIA; ANIMALS; BACTERIAL INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MUCOUS MEMBRANE; URINARY BLADDER;

EID: 84885989341     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.72     Document Type: Review

References (212)

1. Koss, L.G. & Hoda, R.S. Koss's Cytology of the Urinary Tract with Histopathologic Correlations (Springer: New York, London, 2012).
2. Shin, K. et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472, 110-114 (2011).
3. Hicks, R.M. The mammalian urinary bladder: An accommodating organ. Biol. Rev. Camb. Philos. Soc. 50, 215-246 (1975).
4. Negrete, H.O., Lavelle, J.P., Berg, J., Lewis, S.A. & Zeidel, M.L. Permeability properties of the intact mammalian bladder epithelium. Am. J. Physiol. 271, F886-F894 (1996).
5. Wu, X.R., Kong, X.P., Pellicer, A., Kreibich, G. & Sun, T.T. Uroplakins in urothelial biology, function, and disease. Kidney Int. 75, 1153-1165 (2009).
6. Hu, P. et al. Role of membrane proteins in permeability barrier function: Uroplakin ablation elevates urothelial permeability. Am. J. Physiol. Renal Physiol. 283, F1200-F1207 (2002).
7. Hu, P. et al. Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. J. Cell Biol. 151, 961-972 (2000).
8. Zasloff, M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J. Am. Soc. Nephrol. 18, 2810-2816 (2007).
9. Anderson, M. et al. Viable but nonculturable bacteria are present in mouse and human urine specimens. J. Clin. Microbiol. 42, 753-758 (2004).
10. Fouts, D.E. et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J. Transl. Med. 10, 174 (2012).
11. Rivers, B. & Steck, T.R. Viable but nonculturable uropathogenic bacteria are present in the mouse urinary tract following urinary tract infection and antibiotic therapy. Urol. Res. 29, 60-66 (2001).
12. Siddiqui, H.,Nederbragt, A.J., Lagesen,K., Jeansson, S.L. & Jakobsen, K.S. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol. 11, 244 (2011).
13. Coolen, M.J., Post, E., Davis, C.C. & Forney, L.J. Characterization of microbial communities found in the human vagina by analysis of terminal restriction fragment length polymorphisms of 16S rRNA genes. Appl. Environ. Microbiol. 71, 8729-8737 (2005).
14. Ravel, J. et al. Vaginal microbiome of reproductive-Age women. Proc. Natl. Acad. Scie. USA 108 (Suppl 1), 4680-4687 (2011).
15. Pfau, A. & Sacks, T. The bacterial flora of the vaginal vestibule, urethra and vagina in the normal premenopausal woman. J. Urol. 118, 292-295 (1977).
16. Thomas, W.E., Trintchina, E., Forero, M., Vogel, V. & Sokurenko, E.V. Bacterial adhesion to target cells enhanced by shear force. Cell 109, 913-923 (2002).
17. Miller, E., Garcia, T., Hultgren, S. & Oberhauser, A.F. The mechanical properties of E. coli type 1 pili measured by atomic force microscopy techniques. Biophys. J. 91, 3848-3856 (2006).
18. Zakrisson, J.,Wiklund, K., Axner,O. & Andersson,M. The shaft of the type 1 fimbriae regulates an external force to match the FimH catch bond. Biophys. J. 104, 2137-2148 (2013).
19. Parsons, C.L., Boychuk, D., Jones, S., Hurst, R. & Callahan, H. Bladder surface glycosaminoglycans: An epithelial permeability barrier. J. Urol. 143, 139-142 (1990).
20. Parsons, C.L., Stauffer, C., Mulholland, S.G. & Griffith, D.P. Effect of ammonium on bacterial adherence to bladder transitional epithelium. J. Urol. 132, 365-366 (1984).
21. Parsons, C.L., Greenspan, C., Moore, S.W. & Mulholland, S.G. Role of surface mucin in primary antibacterial defense of bladder. Urology 9, 48-52 (1977).
22. Parsons, C.L., Stauffer, C. & Schmidt, J.D. Impairment of antibacterial effect of bladder surface mucin by protamine sulfate. J. Infect. Dis. 144, 180 (1981).
23. Parsons, C.L., Stauffer, C.W. & Schmidt, J.D. Reversible inactivation of bladder surface glycosaminoglycan antibacterial activity by protamine sulfate. Infect. Immun. 56, 1341-1343 (1988).
24. Badalament, R.A. et al. Enhancement of bacillus Calmette-Guerin attachment to the urothelium by removal of the rabbit bladder mucin layer. J. Urol. 147, 482-485 (1992).
25. N'Dow, J., Jordan, N., Robson, C.N., Neal, D.E. & Pearson, J.P. The bladder does not appear to have a dynamic secreted continuous mucous gel layer. J. Urol. 173, 2025-2031 (2005).
26. Svanborg-Eden, C. & Svennerholm, A.M. Secretory immunoglobulin A and G antibodies prevent adhesion of Escherichia coli to human urinary tract epithelial cells. Infect. Immun. 22, 790-797 (1978).
27. Riedasch, G., Heck, P., Rauterberg, E. & Ritz, E. Does low urinary sIgA predispose to urinary tract infectioñ Kidney Int. 23, 759-763 (1983).
28. Morrison, G., Kilanowski, F., Davidson, D. & Dorin, J. Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect. Immun. 70, 3053-3060 (2002).
29. Hiratsuka, T. et al. Structural analysis of human beta-defensin-1 and its significance in urinary tract infection. Nephron 85, 34-40 (2000).
30. Spencer, J.D. et al. Human alpha defensin 5 expression in the human kidney and urinary tract. PLoS One 7, e31712 (2012).
31. Valore, E.V. et al. Human beta-defensin-1: An antimicrobial peptide of urogenital tissues. J. Clin. Invest. 101, 1633-1642 (1998).
32. Chromek, M. et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12, 636-641 (2006).
33. Hertting, O. et al. Vitamin D induction of the human antimicrobial Peptide cathelicidin in the urinary bladder. PLoS One 5, e15580 (2010).
34. Lehmann, J. et al. Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection. BMC Infect. Dis. 2, 20 (2002).
35. Bates, J.M. et al. Tamm-Horsfall protein knockoutmice are more prone to urinary tract infection: Rapid communication. Kidney Int. 65, 791-797 (2004).
36. Pak, J., Pu, Y., Zhang, Z.T., Hasty, D.L. & Wu, X.R. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J. Biol. Chem. 276, 9924-9930 (2001).
37. Saemann, M.D., Weichhart, T., Horl, W.H. & Zlabinger, G.J. Tamm-Horsfall protein: A multilayered defence molecule against urinary tract infection. Eur. J. Clin. Invest. 35, 227-235 (2005).
38. Macpherson, A.J., McCoy, K.D., Johansen, F.E. & Brandtzaeg, P. The immune geography of IgA induction and function. Mucosal Immunol. 1, 11-22 (2008).
39. Gardiner, R.A. et al. Immunohistochemical analysis of the human bladder. Br. J. Urol. 58, 19-25 (1986).
40. Hart, D.N. & Fabre, J.W. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 154, 347-361 (1981).
41. Hjelm, E., Forsum, U. & Klareskog, L. Anti-Ia-reactive cells in the urinary tract of man, guinea-pig, rat andmouse. Scand. J. Immunol. 16, 531-538 (1982).
42. Engel, D.R. et al. CCR2 mediates homeostatic and inflammatory release of Gr1(high) monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection. J. Immunol. 181, 5579-5586 (2008).
43. Schilling, J.D., Martin, S.M., Hung, C.S., Lorenz, R.G. & Hultgren, S.J. Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc. Natl. Acad. Sci. USA 100, 4203-4208 (2003).
44. Gautier, E.L. et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118-1128 (2012).
45. Miller, J.C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888-899 (2012).
46. Christmas, T.J. Lymphocyte sub-populations in the bladderwall in normal bladder, bacterial cystitis and interstitial cystitis. Br. J. Urol. 73, 508-515 (1994).
47. Ingersoll, M.A., Kline, K.A.,Nielsen,H.V. & Hultgren, S.J. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell. Microbiol. 10, 2568-2578 (2008).
48. Sivick, K.E., Schaller, M.A., Smith, S.N. Mobley,H.L. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J. Immunol. 184, 2065-2075 (2010).
49. Jones-Carson, J., Balish, E. & Uehling, D.T. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J. Urol. 161, 338-341 (1999).
50. Porcelli, S., Yockey, C.E., Brenner, M.B. & Balk, S.P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- Alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J. Exp. Med. 178, 1-16 (1993).
51. Tilloy, F. et al. An invariant Tcell receptor alpha chain defines a novel TAPindependent major histocompatibility complex class Ib-restricted alpha/ betaTcell subpopulationinmammals. J.Exp.Med.189, 1907-1921(1999).
52. Treiner, E. et al. Selection of evolutionarily conserved mucosal-Associated invariant T cells by MR1. Nature 422, 164-169 (2003).
53. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282-289 (2008).
54. Hooton, T.M. & Stamm, W.E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 11, 551-581 (1997).
55. Russo, T.A. & Johnson, J.R. Medical and economic impact of extraintestinal infections due to Escherichia coli: Focus on an increasingly important endemic problem. Microbes Infect. 5, 449-456 (2003).
56. Hooton, T.M., Besser, R., Foxman, B., Fritsche, T.R. & Nicolle, L.E. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: A proposed approach toempirical therapy. Clin. Infect. Dis. 39, 75-80 (2004).
57. Ronald, A. The etiology of urinary tract infection: Traditional and emerging pathogens. Dis. Mon. 49, 71-82 (2003).
58. Jones, C.H. et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl. Acad. Sci. USA 92, 2081-2085 (1995).
59. Zhou, G. et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: Evidence from in vitro FimH binding. J. Cell Sci. 114, 4095-4103 (2001).
60. Xie, B. et al. Distinct glycan structures of uroplakins Ia and Ib: Structural basis for the selective binding of FimH adhesin to uroplakin Ia. J. Biol. Chem. 281, 14644-14653 (2006).
61. Wu, X.R., Sun, T.T. & Medina, J.J. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: Relation to urinary tract infections. Proc. Natl. Acad. Sci. USA 93, 9630-9635 (1996).
62. Hultgren, S.J., Porter, T.N., Schaeffer, A.J. & Duncan, J.L. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli. Infect. Immun. 50, 370-377 (1985).
63. Schaeffer, A.J., Schwan,W.R., Hultgren, S.J. &Duncan, J.L. Relationship of type 1 pilus expression in Escherichia coli to ascending urinary tract infections in mice. Infect. Immun. 55, 373-380 (1987).
64. Martinez, J.J.,Mulvey, M.A., Schilling, J.D., Pinkner, J.S. & Hultgren, S.J. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 19, 2803-2812 (2000).
65. Mulvey, M.A. et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494-1497 (1998).
66. Rosen, D.A. et al. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect. Immun. 76, 3346-3356 (2008).
67. Dhakal, B.K. Mulvey,M.A. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J. Biol. Chem. 284, 446-454 (2009).
68. Martinez, J.J. & Hultgren, S.J. Requirement of Rho-family GTPases in the invasion of Type 1-piliated uropathogenic Escherichia coli. Cell. Microbiol. 4, 19-28 (2002).
69. Duncan, M.J., Li, G., Shin, J.S., Carson, J.L. & Abraham, S.N. Bacterial penetration of bladder epithelium through lipid rafts. J. Biol. Chem. 279, 18944-18951 (2004).
70. Eto, D.S., Gordon, H.B., Dhakal, B.K., Jones, T.A. & Mulvey, M.A. Clathrin, AP-2, and the NPXY-binding subset of alternate endocytic adaptors facilitate FimH-mediated bacterial invasion of host cells. Cell. Microbiol. 10, 2553-2567 (2008).
71. Wang, Z. et al. Dynamin2- And endothelial nitric oxide synthase-regulated invasion of bladder epithelial cells by uropathogenic Escherichia coli. J. Cell Biol. 192, 101-110 (2011).
72. Justice, S.S. et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. USA 101, 1333-1338 (2004).
73. Anderson,G.G., Dodson,K.W., Hooton, T.M. & Hultgren, S.J. Intracellular bacterial communities of uropathogenic Escherichia coli in urinary tract pathogenesis. Trends Microbiol. 12, 424-430 (2004).
74. Anderson,G.G. et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301, 105-107 (2003).
75. Rosen, D.A. et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect. Immun. 76, 3337-3345 (2008).
76. Mulvey,M.A., Schilling, J.D. & Hultgren, S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69, 4572-4579 (2001).
77. Rosen, D.A., Hooton, T.M.,Stamm,W.E., Humphrey,P.A. & Hultgren,S.J. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 4, e329 (2007).
78. Czaja, C.A. et al. Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection in women. J. Infect. Dis. 200, 528-536 (2009).
79. Chen, S.L. et al. Genomic diversity and fitness of E. COLI strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci. Transl. Med. 5, 184ra160 (2013).
80. Mysorekar, I.U. & Hultgren, S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. USA 103, 14170-14175 (2006).
81. Schilling, J.D., Lorenz, R.G. & Hultgren, S.J. Effect of trimethoprimsulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect. Immun. 70, 7042-7049 (2002).
82. Kau, A.L. et al. Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect. Immun. 73, 2461-2468 (2005).
83. Kline, K.A. et al. Characterization of a novel murine model of Staphylococcus saprophyticus urinary tract infection reveals roles for Ssp and SdrI in virulence. Infect. Immun. 78, 1943-1951 (2010).
84. Bonkat, G. et al. Microbial biofilm formation and catheter-Associated bacteriuria in patients with suprapubic catheterisation. World J. Urol. 31, 565-571 (2012).
85. Jacobsen, S.M. & Shirtliff, M.E. Proteus mirabilis biofilms and catheterassociated urinary tract infections. Virulence 2, 460-465 (2011).
86. Nielubowicz, G.R. & Mobley, H.L. Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol. 7, 430-441 (2010).
87. Ulett, K.B. et al. Diversity of group B streptococcus serotypes causing urinary tract infection in adults. J. Clin. Microbiol. 47, 2055-2060 (2009).
88. Kline, K.A., Schwartz, D.J., Gilbert, N.M., Hultgren, S.J. & Lewis, A.L. Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli. Infect. Immun. 80, 4186-4194 (2012).
89. Kline, K.A., Schwartz, D.J., Lewis, W.G., Hultgren, S.J. & Lewis, A.L. Immune activation and suppression by groupBstreptococcus in a murine model of urinary tract infection. Infect. Immun. 79, 3588-3595 (2011).
90. Sobel, J.D., Fisher, J.F., Kauffman,C.A. & Newman, C.A. Candida urinary tract infections-epidemiology. Clin. Infect. Dis. 52 (Suppl 6), S433-S436 (2011).
91. Tsai, P.W., Yang, C.Y., Chang, H.T. & Lan, C.Y. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 6, e17755 (2011).
92. Schilling, J.D.,Mulvey, M.A., Vincent, C.D., Lorenz, R.G. & Hultgren, S.J. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J. Immunol. 166, 1148-1155 (2001).
93. Hagberg, L. et al. Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect. Immun. 46, 839-844 (1984).
94. Haraoka, M. et al. Neutrophil recruitment and resistance to urinary tract infection. J. Infect. Dis. 180, 1220-1229 (1999).
95. Yin, X. et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 5, e14223 (2010).
96. Song, J. & Abraham, S.N. Innate and adaptive immune responses in the urinary tract. Eur. J. Clin. Invest. 38 (Suppl 2), 21-28 (2008).
97. Andersen-Nissen, E. et al. Cutting edge: Tlr5-/- mice are more susceptible to Escherichia coli urinary tract infection. J. Immunol. 178, 4717-4720 (2007).
98. Zhang, D. et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303, 1522-1526 (2004).
99. Fischer, H., Yamamoto, M., Akira, S., Beutler, B. & Svanborg, C. Mechanism of pathogen-specific TLR4 activation in the mucosa: Fimbriae, recognition receptors and adaptor protein selection. Eur. J. Immunol. 36, 267-277 (2006).
100. Hopkins, W.J., Gendron-Fitzpatrick, A., Balish, E. & Uehling, D.T. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect. Immun. 66, 2798-2802 (1998).
101. Shahin, R.D., Engberg, I., Hagberg, L. & Svanborg Eden, C. Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J. Immunol. 138, 3475-3480 (1987).
102. Ragnarsdottir, B. et al. TLR- And CXCR1-dependent innate immunity: Insights into the genetics of urinary tract infections. Eur. J. Clin. Invest. 38 (Suppl 2), 12-20 (2008).
103. Ragnarsdottir, B. et al. Toll-like receptor 4 promoter polymorphisms: Common TLR4 variants may protect against severe urinary tract infection. PLoS One 5, e10734 (2010).
104. Ragnarsdottir, B. et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J. Infect. Dis. 196, 475-484 (2007).
105. Wang,H., Min, G.,Glockshuber, R., Sun, T.T. & Kong, X.P. Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: Implications in transmembrane signaling transduction. J. Mol. Biol. 392, 352-361 (2009).
106. Klumpp, D.J. et al. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect. Immun. 74, 5106-5113 (2006).
107. de Man, P. et al. Interleukin-6 induced at mucosal surfaces by gramnegative bacterial infection. Infect Immun 57, 3383-3388 (1989).
108. Jantausch, B.A., O'Donnell, R. &Wiedermann, B.L. Urinary interleukin-6 and interleukin-8 in children with urinary tract infection. Pediatr. Nephrol. (Berlin, Germany) 15, 236-240 (2000).
109. Ko, Y.C. et al. Elevated interleukin-8 levels in the urine of patients with urinary tract infections. Infect. Immun. 61, 1307-1314 (1993).
110. Agace, W.W., Patarroyo, M., Svensson, M., Carlemalm, E. & Svanborg, C. Escherichia coli induces transuroepithelial neutrophil migration by an intercellular adhesion molecule-1-dependent mechanism. Infect. Immun. 63, 4054-4062 (1995).
111. Chan, C.Y. St, John, A.L. & Abraham, S.N.Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38, 349-359 (2013).
112. Duell, B.L. et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J. Immunol. 188, 781-792 (2012).
113. Dielubanza, E.J. & Schaeffer, A.J. Urinary tract infections inwomen. Med. Clin. North Am. 95, 27-41 (2011).
114. McGeachie, J. & Kennedy, A.C. Simplified quantitative methods for bacteriuria and pyuria. J. Clin. Pathol. 16, 32-38 (1963).
115. Daley, J.M., Thomay, A.A., Connolly, M.D., Reichner, J.S. & Albina, J.E. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83, 64-70 (2008).
116. Ingersoll, M.A., Platt, A.M., Potteaux, S. & Randolph, G.J. Monocyte trafficking in acute and chronic inflammation. Trends Immunol. 32, 470-477 (2011).
117. Perdomo, J.J., Gounon, P. & Sansonetti, P.J. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by Shigella flexneri. J. Clin. Invest. 93, 633-643 (1994).
118. Hannan, T.J., Mysorekar, I.U., Hung, C.S., Isaacson-Schmid, M.L. & Hultgren, S.J. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 6, e1001042 (2010).
119. Hopkins, W.J., James, L.J., Balish, E. & Uehling, D.T. Congenital immunodeficiencies in mice increase susceptibility to urinary tract infection. J. Urol. 149, 922-925 (1993).
120. Billips, B.K., Yaggie, R.E., Cashy, J.P., Schaeffer, A.J. & Klumpp, D.J. A live-Attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J. Infect. Dis. 200, 263-272 (2009).
121. Langermann, S. et al. Prevention of mucosal Escherichia coli infection by FimH-Adhesin-based systemic vaccination. Science 276, 607-611 (1997).
122. Alteri, C.J., Hagan, E.C., Sivick, K.E., Smith, S.N. Mobley,H.L. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 5, e1000586 (2009).
123. Uehling, D.T., James, L.J., Hopkins, W.J. & Balish, E. Immunization against urinary tract infection with a multi-valent vaginal vaccine. J. Urol. 146, 223-226 (1991).
124. Uehling, D.T.,Hopkins,W.J., Dahmer, L.A. & Balish, E. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J. Urol. 152, 2308-2311 (1994).
125. Uehling, D.T., Hopkins, W.J., Balish, E., Xing, Y. & Heisey, D.M. Vaginal mucosal immunization for recurrent urinary tract infection: Phase II clinical trial. J. Urol. 157, 2049-2052 (1997).
126. Uehling, D.T., Hopkins, W.J., Beierle, L.M., Kryger, J.V. & Heisey, D.M. Vaginal mucosal immunization for recurrent urinary tract infection: Extended phase II clinical trial. J. Infect. Dis. 183 (Suppl 1), S81-S83 (2001).
127. Sivick, K.E. & Mobley, H.L. Waging war against uropathogenic Escherichia coli: Winning back the urinary tract. Infect. Immun. 78, 568-585 (2009).
128. Thumbikat, P. et al. Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog. 5, e1000415 (2009).
129. Jacobsen, S.M., Stickler, D.J., Mobley, H.L. & Shirtliff, M.E. Complicated catheter-Associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev. 21, 26-59 (2008).
130. Litwin, M.S. & Saigal, C.S., (eds).Vol. NIH Publication No. 07-5512 (ed Public Health Service U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases) (U.S. Government Publishing Office, Washington DC, 2007).
131. Foxman, B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am. J. Med. 113, 5S-13S (2002).
132. McLaughlin, S.P. & Carson, C.C. Urinary tract infections in women. Med. Clin. North Am. 88, 417-429 (2004).
133. Sunden, F., Hakansson, L., Ljunggren, E. & Wullt, B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infectioñ Int. J. Antimicrob. Agents 28 (Suppl 1), S26-S29 (2006).
134. Darouiche, R.O. & Hull, R.A. Bacterial interference for prevention of urinary tract infection: An overview. J. Spinal Cord Med. 23, 136-141 (2000).
135. Matthews, S.J. & Lancaster, J.W. Urinary tract infections in the elderly population. Am. J. Geriatr. Pharmacother. 9, 286-309 (2011).
136. Patterson, T.F. & Andriole, V.T. Detection, significance, and therapy of bacteriuria in pregnancy. Update in the managed health care era. Infect. Dis. Clin. North Am. 11, 593-608 (1997).
137. Roos, V., Schembri, M.A., Ulett, G.C. & Klemm, P. Asymptomatic bacteriuria Escherichia coli strain 83972 carries mutations in the foc locus and is unable to express F1C fimbriae. Microbiology 152, 1799-1806 (2006).
138. Roos, V., Nielsen, E.M. & Klemm, P. Asymptomatic bacteriuria Escherichia coli strains: Adhesins, growth and competition. FEMS Microbiol. Lett. 262, 22-30 (2006).
139. Salvador, E. et al. Comparison of asymptomatic bacteriuria Escherichia coli isolates from healthy individuals versus those from hospital patients shows that long-Term bladder colonization selects for attenuated virulence phenotypes. Infect. Immun. 80, 668-678 (2012).
140. Vejborg, R.M. et al. Identification of genes important for growth of asymptomatic bacteriuria Escherichia coli in urine. Infect. Immun. 80, 3179-3188 (2012).
141. Hooton, T.M. et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N. Engl. J. Med. 343, 992-997 (2000).
142. Beerepoot,M.A. et al. Predictive value of Escherichia coli susceptibility in strains causing asymptomatic bacteriuria for women with recurrent symptomatic urinary tract infections receiving prophylaxis. Clin. Microbiol. Infect. 18, E84-E90 (2012).
143. Wagenlehner, F.M.E. & Naber, K.G. Editorial commentary: Asymptomatic bacteriuria-shift of paradigm. Clin. Infect. Dis. 55, 778-780 (2012).
144. Cai, T. et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: To treat or not to treat? Clin. Infect. Dis. 55, 771-777 (2012).
145. Sunden, F., Hakansson, L., Ljunggren, E. & Wullt, B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J. Urol. 184, 179-185 (2010).
146. Prasad, A., Cevallos, M.E., Riosa, S., Darouiche, R.O. & Trautner, B.W. Abacterial interference strategy for prevention ofUTI in persons practicing intermittent catheterization. Spinal Cord 47, 565-569 (2009).
147. Benson, A.K. et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc. Natl. Acad. Sci. USA 107, 18933-18938 (2010).
148. Fischer, H. et al. Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection. PLoS Pathog. 6, e1001109 (2010).
149. Hawn, T.R. et al. Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. PLoS One 4, e8300 (2009).
150. Artifoni, L. et al. Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J. Urol. 177, 1102-1106 (2007).
151. Zdziarski, J. et al. Host imprints on bacterial genomes-rapid, divergent evolution in individual patients. PLoS Pathog. 6, e1001078 (2010).
152. Hernandez, J.G., Sunden, F., Connolly, J., Svanborg, C. & Wullt, B. Genetic control of the variable innate immune response to asymptomatic bacteriuria. PLoS One 6, e28289 (2011).
153. Ferlay, J. et al. Estimates of the cancer incidence andmortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007).
154. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
155. Morales, A., Eidinger, D. & Bruce, A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180-183 (1976).
156. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59, 997-1008 (2011).
157. Prescott, S., James, K., Hargreave, T.B., Chisholm, G.D. & Smyth, J.F. Intravesical Evans strainBCGtherapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol. 147, 1636-1642 (1992).
158. Kelley, D.R. et al. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Effect of bacillus Calmette-Guerin viability on treatment results. J. Urol. 134, 48-53 (1985).
159. Ratliff, T.L., Palmer, J.O., McGarr, J.A. & Brown, E.J. Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res. 47, 1762-1766 (1987).
160. Kavoussi, L.R., Brown, E.J., Ritchey, J.K. & Ratliff, T.L. Fibronectinmediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J. Clin. Invest. 85, 62-67 (1990).
161. Teppema, J.S., de Boer, E.C., Steerenberg, P.A. & van der Meijden, A.P. Morphological aspects of the interaction of Bacillus Calmette-Guerin with urothelial bladder cells in vivo and in vitro: Relevance for antitumor activity? Urol. Res. 20, 219-228 (1992).
162. Kuroda, K., Brown, E.J., Telle, W.B., Russell, D.G. & Ratliff, T.L. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J. Clin. Invest. 91, 69-76 (1993).
163. Redelman-Sidi, G., Iyer, G., Solit, D.B. & Glickman, M.S. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res. 73, 1156-1167 (2013).
164. Wu, X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat. Rev. Cancer 5, 713-725 (2005).
165. Puzio-Kuter, A.M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23, 675-680 (2009).
166. Becich, M.J., Carroll, S. & Ratliff, T.L. Internalization of bacille Calmette-Guerin by bladder tumor cells. J. Urol. 145, 1316-1324 (1991).
167. Alexandroff, A.B., Nicholson, S., Patel, P.M. & Jackson, A.M. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy 2, 551-560 (2010).
168. Brandau, S. & Suttmann, H. Thirty years of BCG immunotherapy for nonmuscle invasive bladder cancer: A success story with room for improvement. Biomed. Pharmacother. 61, 299-305 (2007).
169. De Boer, E.C. et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol. Immunother. 33, 411-416 (1991).
170. Bisiaux, A. et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J. Urol. 181, 1571-1580 (2009).
171. Biot, C. et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci. Transl. Med. 4, 137ra172 (2012).
172. Saban, M.R. et al. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol. 8, 6 (2007).
173. Jackson, A.M. et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin. Exp. Immunol. 99, 369-375 (1995).
174. Simons, M.P., O'Donnell, M.A. & Griffith, T.S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26, 341-345 (2008).
175. Hanada, T. et al. Prognostic value of tumor-Associated macrophage count in human bladder cancer. Int. J. Urol. 7, 263-269 (2000).
176. Takayama, H. et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J. Urol. 181, 1894-1900 (2009).
177. Ayari, C. et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur. Urol. 55, 1386-1395 (2009).
178. Ratliff, T.L., Gillen, D. & Catalona, W.J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137, 155-158 (1987).
179. Ratliff, T.L., Ritchey, J.K., Yuan, J.J., Andriole, G.L. Catalona,W.J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150, 1018-1023 (1993).
180. Brandau, S. et al. NK cells are essential for effectiveBCGimmunotherapy. Int. J. Cancer 92, 697-702 (2001).
181. Suttmann, H. et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66, 8250-8257 (2006).
182. De Boer, E.C., Rooijakkers, S.J., Schamhart, D.H. & Kurth, K.H. Cytokine gene expression in a mouse model: The first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J. Urol. 170, 2004-2008 (2003).
183. Nadler, R. et al. Interleukin 10 induced augmentation of delayed-Type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin. Exp. Immunol. 131, 206-216 (2003).
184. McAveney, K.M., Gomella, L.G. & Lattime, E.C. Induction of TH1- And TH2-Associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol. Immunother. 39, 401-406 (1994).
185. Riemensberger, J., Bohle, A. & Brandau, S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin. Exp. Immunol. 127, 20-26 (2002).
186. Bockholt, N.A. et al. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guerin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. J. Urol. 187, 2228-2235 (2012).
187. Saint, F. et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J. Urol. 167, 364-367 (2002).
188. Zuiverloon, T.C. et al. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: A systematic review. Eur. Urol. 61, 128-145 (2012).
189. Saint, F. et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int. J. Cancer 107, 434-440 (2003).
190. Watanabe, E. et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol. Immunother. 52, 481-486 (2003).
191. de Reijke, T.M., de Boer, E.C., Kurth, K.H. & Schamhart, D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value. J. Urol. 155, 477-482 (1996).
192. Margel, D., Pevsner-Fischer, M., Baniel, J., Yossepowitch, O. & Cohen, I.R. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur. Urol. 59, 113-119 (2011).
193. Schwentner, C., Stenzl, A. & Gakis, G. Monitoring high-risk bladder cancer. Curr. Opin. Urol. 22, 421-426 (2012).
194. Kucukgergin, C. et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene 511, 7-11 (2012).
195. Jaiswal, P.K., Singh, V., Srivastava, P. & Mittal, R.D. Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene 519, 128-134 (2013).
196. Basturk, B., Yavascaoglu, I., Oral, B.,Goral, G. Oktay, B. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy. Cytokine 35, 1-5 (2006).
197. Mungan, N.A. & Witjes, J.A. Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br. J. Urol. 82, 213-223 (1998).
198. Zhao, J., Wang, Z., Chen, X., Wang, J. & Li, J. Effects of intravesical liposome-mediated human beta-defensin-2 gene transfection in a mouse urinary tract infection model. Microbiol. Immunol. 55, 217-223 (2011).
199. Cusumano, C.K. et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci. Transl. Med. 3, 109ra115 (2011).
200. Bishop, B.L. et al. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat. Med. 13, 625-630 (2007).
201. Olbert, P.J. et al. In vitro and in vivo effects of CpG- Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Res. 29, 2067-2076 (2009).
202. Xiao, Z., Mak, A., Koch, K. & Moore, R.B. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model. BJU Int. 112, E201-E210 (2013).
203. O'Donnell, M.A. et al. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J. Immunol. 163, 4246-4252 (1999).
204. Luo, Y., Chen, X., Downs, T.M., DeWolf, W.C. & O'Donnell, M.A. IFNalpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J. Immunol. 162, 2399-2405 (1999).
205. Gan, Y.H., Zhang, Y., Khoo, H.E. & Esuvaranathan, K. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Eur. J. Cancer 35, 1123-1129 (1999).
206. Stricker, P. et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 48, 957-961. discussion 961-952 (1996).
207. Nepple, K.G., Lightfoot, A.J., Rosevear, H.M., O'Donnell, M.A. & Lamm, D.L. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J. Urol. 184, 1915-1919 (2010).
208. Luo, Y., Henning, J. & O'Donnell, M.A. Th1 cytokine-secreting recombinantMycobacterium bovis bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer. Clin. Dev. Immunol. 2011, 728930 (2011).
209. Luo, Y., Chen, X., Han, R. & O'Donnell, M.A. Recombinant Bacille Calmette-Guerin (BCG) expressing human interferon-Alpha 2B demonstrates enhanced immunogenicity. Clin. Exp. Immunol. 123, 264-270 (2001).
210. Liu, W., O'Donnell, M.A., Chen, X., Han, R. & Luo, Y. Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-Alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol. Immunother. 58, 1647-1655 (2009).
211. Grode, L. et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472-2479 (2005).
212. Lamm, D.L., Thor,D.E.,Winters,W.D., Stogdill, V.D. & Radwin, H.M.BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses. Cancer 48, 82-88 (1981).